高强度他汀治疗降低慢性肢体威胁性缺血患者下肢旁路术后截肢与再干预风险
基于IBM MarketScan数据库纳入2008至2017年因慢性肢体威胁性缺血行下肢旁路术的成人患者25907例,按他汀强度分为高强度、低强度和有限他汀治疗三组。高强度他汀组再干预风险(HR 0.48)和截肢风险(HR 0.27)均显著低于有限治疗组,且存在剂量依赖效应。
要点
- 下肢旁路术后维持高强度他汀与再干预风险降低相关(HR 0.48)。
- 高强度他汀与截肢风险降低相关(HR 0.27),且独立于自体静脉移植。
- 再干预患者中高强度他汀与后续截肢风险降低相关(HR 0.21)。
核心结论
- 慢性肢体威胁性缺血患者下肢旁路术后接受高强度他汀治疗,相比低强度他汀或有限他汀使用,再干预和截肢风险显著降低。
- 作者认为这些数据提示,血运重建后应尽可能将慢性肢体威胁性缺血患者的他汀上调至和/或维持在高强度。
研究设计与样本
- 使用IBM MarketScan数据库识别2008年至2017年间因慢性肢体威胁性缺血行下肢旁路术的18至99岁成人患者。
- 排除无药物报销保险覆盖或旁路术前已截肢者,利用药房索赔和国家药品代码定义他汀强度。
- 将患者分为高强度、低强度和有限他汀治疗三组,采用Kaplan-Meier曲线和风险校正Cox比例风险模型分析他汀强度与再干预和/或大截肢的关联。
主要发现
- 共识别25907例因慢性肢体威胁性缺血行下肢旁路术患者,其中6696例(26%)维持高强度他汀,9297例(36%)低强度他汀,9914例(38%)术后他汀药房索赔不一致。
- 下肢旁路术后,6649例(25.6%)需要再干预,2550例(9.8%)随访期间发生大截肢。
- 高强度他汀组相比有限他汀治疗组,再干预风险显著降低(HR 0.48;95%CI 0.45-0.51;P<.001),截肢风险显著降低(HR 0.27;95%CI 0.24-0.30;P<.001)。
- 风险校正模型中,相比低强度他汀组,这些结局存在剂量依赖效应,且独立于下肢旁路术是否使用自体静脉移植。
- 在需要再干预的患者中,高强度他汀治疗也显著降低后续截肢的HR(HR 0.21;95%CI 0.18-0.25;P<.001)。
临床怎么用
- 作者认为,慢性肢体威胁性缺血患者血运重建后应尽可能将他汀上调至和/或维持在高强度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statins are considered standard-of-care medical therapy for patients undergoing lower extremity bypass (LEB) procedures for chronic limb-threatening ischemia (CLTI). It is unclear, however, whether up-titrating and maintaining patients on higher-intensity statin medications following LEB improves limb salvage outcomes. This study was designed to evaluate whether high-intensity statin therapy impacts the risk of amputation and reintervention following LEB for patients with CLTI. METHODS: The IBM MarketScan database was used to identify adult patients (18-99 years old) who underwent a LEB for CLTI between 2008 and 2017. Patients lacking insurance covering drug reimbursement or those who already had undergone amputation before time of bypass were excluded. Using pharmacy claims and national drug codes to define statin intensity, patients were stratified into three groups: high-intensity, low-intensity, and limited statin therapy. The association between intensity of statin therapy and need for reintervention and/or major amputation after LEB was analyzed using Kaplan-Meier curves and risk-adjusted Cox proportional hazard models. RESULTS: A total of 25,907 patients who underwent LEB for CLTI were identified, of which 6696 (26%) were maintained on high-dose statins, 9297 (36%) were on low-dose statins, and 9914 (38%) had inconsistent pharmacy claims for statin therapy after surgery. Patients on high-intensity statins were, on average, younger and more likely to be male with comorbid disease (diabetes, hypertension, hyperlipidemia, obesity, renal insufficiency, ischemic heart disease, cerebrovascular disease, and tobacco abuse) than patients on low-intensity statins or limited statin therapy (P < .001 for all comparisons). Following LEB, 6649 patients (25.6%) required a reintervention, and 2550 patients (9.8%) went on to have a major amputation during follow-up. Patients maintained on high-intensity statins after LEB had a significantly lower likelihood of requiring a reintervention (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.45-0.51; P < .001) or amputation (HR, 0.27; 95% CI, 0.24-0.30; P < .001) as compared with patients on limited statin therapy. Further, there was a dose-dependent effect for these outcomes relative to patients on low-intensity statins in risk-adjusted models, and it was independent of whether an autologous vein graft was used for the LEB. Finally, among patients who underwent a reintervention, high-dose statin therapy also significantly reduced the HR for subsequent amputation (HR, 0.21; 95% CI, 0.18-0.25; P < .001). CONCLUSIONS: Patients with CLTI on high-intensity therapy following LEB had a significantly lower risk of requiring subsequent reintervention and amputation when compared with patients on low-intensity statins or with limited statin use. These data suggest that patients with CLTI should be up-titrated and/or maintained on high-intensity statins following revascularization whenever possible.
引用
- He JJ, Horns JJ, Kraiss LW, et al. High-intensity statin therapy reduces risk of amputation and reintervention among patients undergoing lower extremity bypass for chronic limb-threatening ischemia. J Vasc Surg. 2022. PMID: 36115522. doi:10.1016/j.jvs.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。